Pharma Pipeline Intelligence MCP avatar

Pharma Pipeline Intelligence MCP

Pricing

Pay per usage

Go to Apify Store
Pharma Pipeline Intelligence MCP

Pharma Pipeline Intelligence MCP

Competitive intelligence MCP server for pharmaceutical AI agents

Pricing

Pay per usage

Rating

0.0

(0)

Developer

AutomateLab

AutomateLab

Maintained by Community

Actor stats

0

Bookmarked

1

Total users

1

Monthly active users

3 days ago

Last modified

Categories

Share

Pharma Pipeline Intelligence MCP Server

View on Apify | Use on Apify Store

AI agents for pharmaceutical competitive intelligence — clinical trials, FDA/EMA approvals, adverse event signals, patent cliffs, and regulatory pathways across 7 government databases. Generates composite Pipeline Threat Scores (0-100) for biotech investors, business development teams, and medical affairs.


1. Purpose Statement

Pharma Pipeline Intelligence MCP is an MCP (Model Context Protocol) server that gives AI agents access to pharmaceutical pipeline data across 7 government databases, producing composite Pipeline Threat Scores (0-100) for competitive intelligence. AI agents performing biotech investment analysis, competitive landscape monitoring, patent cliff assessment, safety signal surveillance, or regulatory pathway planning query real-time clinical trials, FDA/EMA approvals, adverse event reports, patent portfolios, and publication trends without requiring API keys or manual database navigation.

Built for: AI agents doing biotech investment due diligence, competitive landscape monitoring for business development, patent cliff and generic entry strategy, safety signal surveillance for medical affairs, regulatory pathway planning, and research strategy for emerging therapeutic areas.


2. Quick Start

Add to your MCP client:

{
"mcpServers": {
"pharma-pipeline-intelligence-mcp": {
"url": "https://red-cars--pharma-pipeline-intelligence-mcp.apify.actor/mcp"
}
}
}

AI agents can now assess competitive pressure in any therapeutic area, evaluate drug safety signals, monitor patent cliffs, and track regulatory approval landscapes across FDA, EMA, ClinicalTrials.gov, USPTO, and PubMed.


3. When to Call This MCP

Use Pharma Pipeline Intelligence MCP when you need to:

  • Assess competitive pipeline threats — Get composite Pipeline Threat Scores (0-100) for any drug or therapeutic area
  • Monitor clinical trial activity — Track Phase 1/2/3/4 trials by drug, condition, or company
  • Analyze competitive landscapes — Side-by-side FDA vs EMA approval status with threat scoring
  • Detect adverse event signals — Screen FDA FAERS reports for divergence scores and MedDRA reactions
  • Track patent cliffs — Monitor USPTO patent portfolios with expiry dates and First-Mover Advantage scores
  • Compare regulatory pathways — Analyze FDA vs EMA approval gaps and authorization timelines
  • Monitor drug recalls — Track FDA Class I/II/III recalls by drug or manufacturer
  • Assess literature momentum — Measure publication acceleration and journal velocity via PubMed
  • Generate full threat reports — Composite analysis fanning out to all 7 data sources simultaneously
  • Biotech investment due diligence — Validate investment theses with pipeline threat, safety, and IP analysis
  • Business development intelligence — Monitor competitive landscapes for deal sourcing
  • Patent cliff strategy — Assess generic entry risk and exclusivity remaining
  • Medical affairs surveillance — Track emerging safety signals before regulatory action
  • Regulatory planning — Plan market access across FDA and EMA jurisdictions

4. What Data Can You Access?

Data TypeSourceExample
Clinical TrialsClinicalTrials.govPhase distribution, enrollment, status, sponsors
FDA Drug ApprovalsopenFDA Drug ApprovalsNDA/BLA/ANDA approvals by drug class
Adverse Event ReportsopenFDA FAERSSerious events, deaths, hospitalizations, MedDRA terms
Drug RecallsFDA EnforcementClass I/II/III recall notices
Patent PortfolioUSPTOFiling counts, expiry dates, years of exclusivity
Publication TrendsPubMedYearly counts, acceleration ratios, top journals

Note: EMA authorizations are not available via public API and have been dropped from this MCP.


5. Why Use Pharma Pipeline Intelligence MCP?

The problem: Pharmaceutical competitive intelligence — clinical trials, FDA/EMA approvals, adverse event signals, patent cliffs, and regulatory pathways — requires searching 7+ government databases and synthesizing findings into actionable intelligence. For biotech investors, business development teams, medical affairs, and patent attorneys, this data is essential for investment decisions, deal sourcing, safety surveillance, and market access planning. Manual research takes days across disconnected ClinicalTrials.gov, FDA, EMA, USPTO, and PubMed systems.

The solution: AI agents use Pharma Pipeline Intelligence MCP to get instant, structured competitive intelligence on any drug or therapeutic area — the pharmaceutical intelligence layer for AI agents doing biotech research, BD monitoring, and regulatory planning.

Key benefits:

  • Pipeline Threat Scoring — Composite 0-100 scores combining competitive pressure, safety signals, literature momentum, and IP position
  • 7 government databases queried simultaneously — ClinicalTrials.gov, FDA, FAERS, USPTO, PubMed all in one call
  • 4 scoring sub-models — Pipeline Threat, First-Mover Advantage, Adverse Event Divergence, Literature Momentum
  • Adverse event signal detection — MedDRA reaction aggregation with divergence scoring (NORMAL/ELEVATED/CONCERNING/CRITICAL)
  • Patent cliff monitoring — USPTO portfolio analysis with years of exclusivity remaining and FMA scores
  • Regulatory gap analysis — FDA approval status with gap metrics (EMA unavailable)
  • No API key required — All data sources are free government APIs, works immediately
  • Parallel data fetching — Promise.allSettled orchestration for fast responses across all sources

6. Features

Pipeline Threat Scoring (0-100) Composite score measuring competitive pressure in any therapeutic area. Combines Phase 3 competitor counts (8 pts each, cap 40), trial volume (2 pts each, cap 20), FDA approvals (5 pts each, cap 15), and competitor recalls (-5 pts each, cap -15).

First-Mover Advantage Index (0-100) Assesses defensive position via patent portfolio breadth (6 pts/patent, cap 30), exclusivity duration (2.5 pts/year, cap 25), trial phase lead (6.25 pts/phase, cap 25), and FDA approval count (10 pts/approval, cap 20). Patent cliff warning triggers when <2 years remaining.

Adverse Event Divergence Scoring (0-100) Analyzes FDA FAERS reports for safety signals. Components: death reports (7 pts each, cap 35), serious event ratio (ratio x 50, cap 25, triggers at >30%), hospitalization burden (4 pts/report, cap 20), log-normalized volume (log2 x 3, cap 20). Divergence levels: NORMAL (0-24), ELEVATED (25-49), CONCERNING (50-74), CRITICAL (75-100).

Literature Momentum Scoring (0-100) Measures publication acceleration via PubMed. Components: volume (3 pts/pub, cap 30), recency (5 pts/recent pub, cap 30), acceleration ratio (25, triggers at 20% growth threshold), journal diversity (3 pts/journal, cap 15).

Parallel 6-Source Orchestration The generate_pipeline_threat_report tool fans out to all 6 data sources simultaneously via Promise.allSettled. Each source gets 120-second timeout. Partial failure returns available data with warning signals.

Phase Normalization Handles both Arabic ("Phase 3") and Roman numeral ("Phase III") phase labels across ClinicalTrials.gov data.


7. How It Compares to Alternatives

AspectOur MCPApifyForgeCitelineCortellisGlobalData
Price$0.04-$0.15/call$0.045/call (flat)$15,000-$50,000/year$15,000+/year$20,000+/year
API accessMCP (AI-native)MCPREST (expensive)RESTREST
Tool count8 tools8 toolsFull databaseFull databaseFull database
Data sources6 (government)7 (incl. EMA)Commercial + govtCommercial + govtCommercial
Scoring models4 sub-models4 sub-modelsLimitedLimitedLimited
Composite reportYes (threat report)YesManual synthesisManual synthesisManual synthesis
AI agent integrationNative MCPNative MCPNo MCPNo MCPNo MCP
No API key requiredYesYesNoNoNo
Public GitHub repoYesNoN/AN/AN/A
LLM/AI agent SEOYes (public)NoNoNoNo

Why choose our MCP:

  • MCP protocol is designed for AI agent integration — call pharma intelligence tools with natural language
  • Public GitHub repository + llms.txt for AI agent discovery — ApifyForge version is private, not findable by AI agents
  • Tiered pricing by value ($0.04-$0.15) vs ApifyForge flat $0.045 — composite reports cost more, simple lookups cost less
  • 4 built-in scoring sub-models — commercial platforms require manual analysis
  • Commercial platforms (Citeline, Cortellis, GlobalData) cost $15,000-$50,000/year — our MCP is fractions of a cent per call
  • No API key required — all data sources are free government APIs, works immediately

Competitor APIs:


8. Use Cases for Pharma Pipeline Intelligence

Biotech Investment Due Diligence

Persona: Biotech investor validating investment thesis for GLP-1 franchise

AI agent: "Assess competitive threat to Novo Nordisk's semaglutide franchise over next 5 years"
MCP call: generate_pipeline_threat_report({ company: "Novo Nordisk", drug: "semaglutide", indication: "obesity" })
Returns: compositeScore: 64, riskLevel: HIGH, 8 Phase 3 competitors, 11 years exclusivity, elevated adverse event divergence

Competitive Landscape Monitoring for BD

Persona: Business development team identifying deal targets in CDK4/6 inhibitor space

AI agent: "Who are the top Phase 3 competitors to our CDK4/6 inhibitor in metastatic breast cancer?"
MCP call: analyze_competitive_landscape({ query: "CDK4/6 inhibitor breast cancer" })
+ search_drug_pipeline({ query: "CDK4/6 breast cancer", phase: "PHASE3" })
Returns: FDA approvals, active trial count, Pipeline Threat Score, ranked Phase 3 competitors

Patent Cliff and Generic Entry Strategy

Persona: Patent attorney assessing Keytruda patent expiry and generic threat

AI agent: "When does Keytruda's patent estate expire and what is the generic entry risk?"
MCP call: track_patent_exclusivity({ query: "pembrolizumab" })
+ monitor_drug_recalls({ query: "pembrolizumab", classification: "Class I" })
Returns: patentCount: 23, earliestExpiry: 2033-06-15, yearsExclusivityRemaining: 7, FMA Score: 82, patent cliff warning

Safety Signal Surveillance for Medical Affairs

Persona: Medical affairs team monitoring emerging safety signals for new drug launch

AI agent: "Are there emerging adverse event signals for our GLP-1 drug in the FDA database?"
MCP call: detect_adverse_event_signals({ query: "GLP-1", limit: 500 })
+ assess_literature_momentum({ query: "GLP-1 safety signals" })
Returns: divergenceScore: 45, divergenceLevel: ELEVATED, 23 death reports, seriousRatio: 0.31, top MedDRA reactions

Regulatory Pathway Planning

Persona: Regulatory affairs team planning market entry

AI agent: "What is the FDA approval status and regulatory gap for PD-1 inhibitors?"
MCP call: compare_regulatory_pathways({ query: "PD-1 inhibitor" })
Returns: FDA approvals list, regulatoryGapMetric: null, note explaining EMA unavailability

9. How to Connect Pharma Pipeline Intelligence MCP Server to Your AI Client

Step 1: Get your Apify API token (optional)

Sign up at apify.com and copy your API token from the console. The MCP works without an API token for tool calls, but Apify authentication may be required by some MCP clients.

Step 2: Add the MCP server to your client

Claude Desktop: Add to ~/Library/Application Support/Claude/claude_desktop_config.json:

{
"mcpServers": {
"pharma-pipeline-intelligence-mcp": {
"url": "https://red-cars--pharma-pipeline-intelligence-mcp.apify.actor/mcp"
}
}
}

Cursor/Windsurf: Add to MCP settings:

{
"mcpServers": {
"pharma-pipeline-intelligence-mcp": {
"url": "https://red-cars--pharma-pipeline-intelligence-mcp.apify.actor/mcp"
}
}
}

Step 3: Start querying

AI agent: "Generate a pipeline threat report for Eli Lilly's tirzepatide in the obesity indication"

Step 4: Retrieve results

The MCP returns structured JSON with composite scores, risk levels, sub-model breakdowns, and signal arrays.


10. MCP Tools

ToolPriceDescription
search_drug_pipeline$0.05Search ClinicalTrials.gov for clinical trials by drug, condition, or therapeutic area
analyze_competitive_landscape$0.08Side-by-side FDA analysis with Pipeline Threat Score
detect_adverse_event_signals$0.06Analyze FDA FAERS reports for adverse event signals with Divergence Score
track_patent_exclusivity$0.05USPTO patent portfolio analysis with First-Mover Advantage Score
compare_regulatory_pathways$0.05FDA approval status and regulatory gap analysis (EMA unavailable)
monitor_drug_recalls$0.04Search FDA drug recall database by drug, manufacturer, or classification
assess_literature_momentum$0.05PubMed publication trend analysis with Literature Momentum Score
generate_pipeline_threat_report$0.15Full composite report: 4 sub-model scores + composite Pipeline Threat Score (0-100)

11. Tool Parameters

search_drug_pipeline

ParameterTypeRequiredDescription
querystringYesDrug name, condition, or therapeutic area
statusstringNoRECRUITING, ACTIVE_NOT_RECRUITING, COMPLETED
phasestringNoPHASE1, PHASE2, PHASE3, PHASE4
maxResultsintegerNoMaximum results (default: 50, max: 50)

When to call: Persona: Biotech investor or business development analyst. Scenario: "Research the clinical trial landscape for a therapeutic area to assess competitive intensity."

Example AI prompt: "Find all Phase 3 trials for GLP-1 agonists that are currently recruiting, show sponsors, enrollment, and estimated completion dates."


analyze_competitive_landscape

ParameterTypeRequiredDescription
querystringYesDrug class, therapeutic area, or active ingredient

When to call: Persona: Business development team or competitive intelligence analyst. Scenario: "Assess the competitive landscape for a drug class to identify threats and opportunities."

Example AI prompt: "Analyze the competitive landscape for CDK4/6 inhibitors in breast cancer — show FDA approvals, active trial count, and pipeline threat score."


detect_adverse_event_signals

ParameterTypeRequiredDescription
querystringYesDrug name or active ingredient
limitintegerNoMax FAERS records (default: 100, max: 500)

When to call: Persona: Medical affairs team or pharmacovigilance specialist. Scenario: "Monitor adverse event reports for emerging safety signals."

Example AI prompt: "Screen FDA FAERS for adverse event signals on semaglutide — show serious events, deaths, hospitalizations, and top MedDRA reactions. Limit to 500 most recent reports."


track_patent_exclusivity

ParameterTypeRequiredDescription
querystringYesDrug name, compound, mechanism, or assignee

When to call: Persona: Patent attorney or regulatory affairs team. Scenario: "Assess patent cliff risk and exclusivity remaining for a drug."

Example AI prompt: "Track patent exclusivity for pembrolizumab — show patent count, filing dates, expiry dates, years of exclusivity remaining, and First-Mover Advantage score."


compare_regulatory_pathways

ParameterTypeRequiredDescription
querystringYesDrug name, active substance, or therapeutic area

When to call: Persona: Regulatory affairs team or market access planner. Scenario: "Check FDA approval status for market entry planning."

Example AI prompt: "Compare regulatory status for GLP-1 drugs — show FDA approvals and note EMA unavailability."


monitor_drug_recalls

ParameterTypeRequiredDescription
querystringYesDrug name, manufacturer, or recall reason
classificationstringNoClass I, Class II, Class III

When to call: Persona: Pharmacy manager or drug safety AI. Scenario: "Check for active recalls on a drug class before dispensing."

Example AI prompt: "Find all FDA Class I and II recalls for metformin in the last 3 years — show classification, reason, and recalling firm."


assess_literature_momentum

ParameterTypeRequiredDescription
querystringYesDrug name, condition, mechanism, or research topic
maxResultsintegerNoMaximum publications (default: 50)

When to call: Persona: Research strategist or medical affairs team. Scenario: "Assess publication trends and emerging research momentum for a drug."

Example AI prompt: "Assess literature momentum for GLP-1 obesity therapeutics — show yearly publication counts, acceleration ratio, top journals, and Literature Momentum Score."


generate_pipeline_threat_report

ParameterTypeRequiredDescription
companystringYesCompany name
drugstringYesDrug name
indicationstringNoAppended to ClinicalTrials.gov query

When to call: Persona: Biotech investor or competitive intelligence analyst. Scenario: "Generate comprehensive competitive threat analysis for a drug franchise."

Example AI prompt: "Generate a full pipeline threat report for Novo Nordisk's semaglutide in obesity — include all 4 sub-model scores and composite threat score."


12. Connection Examples

cURL

curl -X POST "https://red-cars--pharma-pipeline-intelligence-mcp.apify.actor/mcp" \
-H "Authorization: Bearer YOUR_APIFY_TOKEN" \
-H "Content-Type: application/json" \
-d '{
"tool": "analyze_competitive_landscape",
"params": { "query": "GLP-1 agonist obesity" }
}'

Node.js

const response = await fetch('https://red-cars--pharma-pipeline-intelligence-mcp.apify.actor/mcp', {
method: 'POST',
headers: {
'Authorization': 'Bearer YOUR_APIFY_TOKEN',
'Content-Type': 'application/json'
},
body: JSON.stringify({
tool: 'generate_pipeline_threat_report',
params: { company: 'Novo Nordisk', drug: 'semaglutide', indication: 'obesity' }
})
});
const data = await response.json();
console.log(data.result.compositeScore, data.result.riskLevel);

Python

import httpx
import json
url = "https://red-cars--pharma-pipeline-intelligence-mcp.apify.actor/mcp"
payload = {
"tool": "track_patent_exclusivity",
"params": { "query": "pembrolizumab" }
}
headers = {"Authorization": "Bearer YOUR_APIFY_TOKEN"}
response = httpx.post(url, headers=headers, json=payload)
report = json.loads(response.json()["result"])
print(f"First-Mover Advantage: {report['firstMoverAdvantageScore']}")

13. Output Example

{
"status": "success",
"result": {
"company": "Novo Nordisk",
"drug": "semaglutide",
"reportDate": "2026-04-22",
"compositeScore": 64,
"riskLevel": "HIGH",
"pipelineThreat": {
"score": 72,
"competitorCount": 8,
"phaseDistribution": { "Phase 1": 23, "Phase 2": 45, "Phase 3": 34, "Phase 4": 25 },
"sameIndicationTrials": 127,
"recentApprovals": 4,
"recentRecalls": 0,
"threatLevel": "HIGH",
"signals": [
"8 Phase 3 competitors in same indication",
"4 recent FDA approvals in drug class"
]
},
"firstMoverAdvantage": {
"score": 78,
"patentsCovering": 12,
"earliestPatentExpiry": "2037-03-15",
"yearsOfExclusivity": 11,
"trialPhaseLead": 4,
"approvalPathwayClear": true,
"signals": [
"11 years exclusivity remaining",
"Phase 4 lead indicates established market position"
]
},
"adverseEventDivergence": {
"score": 45,
"totalReports": 2847,
"seriousEvents": 892,
"deathReports": 23,
"hospitalizationReports": 341,
"seriousRatio": 0.313,
"divergenceLevel": "ELEVATED",
"topReactions": [
{ "term": "NAUSEA", "count": 423 },
{ "term": "VOMITING", "count": 312 }
],
"signals": [
"Serious ratio exceeds 30% threshold"
]
},
"literatureMomentum": {
"score": 68,
"publicationCount": 234,
"recentPublications": 89,
"yearlyTrend": { "2022": 42, "2023": 58, "2024": 76, "2025": 58 },
"accelerating": true,
"topJournals": ["NEJM", "The Lancet", "JAMA", "BMJ", "Nature Medicine"],
"signals": [
"31% publication growth exceeds 20% threshold"
]
},
"allSignals": [
"8 Phase 3 competitors in same indication",
"4 recent FDA approvals in drug class",
"11 years exclusivity remaining",
"Serious ratio exceeds 30% threshold",
"31% publication growth exceeds 20% threshold"
]
}
}

14. Output Fields

FieldDescription
compositeScorePipeline Threat Score 0-100 (weighted average of 4 sub-models)
riskLevelLOW (0-25), MODERATE (26-50), HIGH (51-75), CRITICAL (76-100)
pipelineThreatSub-model score for competitive pressure (Phase 3 competitors, trial volume, approvals, recalls)
firstMoverAdvantageSub-model score for defensive position (patents, exclusivity, trial phase, approvals)
adverseEventDivergenceSub-model score for safety signal intensity (deaths, serious ratio, hospitalizations)
literatureMomentumSub-model score for publication acceleration (volume, recency, acceleration, journal diversity)
threatLevelRisk classification for pipeline threat sub-model
divergenceLevelSafety signal classification: NORMAL, ELEVATED, CONCERNING, CRITICAL
acceleratingBoolean — true if publication growth exceeds 20% threshold
patentCliffWarningBoolean — true if <2 years exclusivity remaining
signalsArray of human-readable intelligence signals from each sub-model
sourceData sources queried (ClinicalTrials.gov, FDA, USPTO, PubMed)

15. How Much Does It Cost?

PPE (Pay-Per-Event) pricing — $0.04 to $0.15 per tool call.

ToolPrice
search_drug_pipeline$0.05
analyze_competitive_landscape$0.08
detect_adverse_event_signals$0.06
track_patent_exclusivity$0.05
compare_regulatory_pathways$0.05
monitor_drug_recalls$0.04
assess_literature_momentum$0.05
generate_pipeline_threat_report$0.15

No subscription. No monthly fee. Pay only when AI agents use the tools.

Monthly cost estimates:

ScenarioCallsCost
Quick test (1 tool)1$0.04-$0.15
Spot check (3 tools)3$0.12-$0.45
Weekly landscape15$0.60-$2.25
Monthly surveillance50$2.00-$7.50
Daily monitoring200$8.00-$30.00

Comparison: Commercial platforms (Citeline, Cortellis, GlobalData) = $15,000-$50,000/year. Our MCP provides pharmaceutical competitive intelligence at under 0.02% of the cost.


16. How It Works

Phase 1: Request parsing

AI agent sends tool call via MCP protocol. Server parses tool name and parameters.

Phase 2: Parallel data fetching

For generate_pipeline_threat_report, the server fans out to all 6 data sources simultaneously:

  • ClinicalTrials.gov (drug + indication query)
  • openFDA Drug Approvals (drug class query)
  • openFDA FAERS (drug, limit: 100)
  • FDA Enforcement (drug)
  • USPTO (drug)
  • PubMed (drug)

Each source gets 120-second timeout. Promise.allSettled ensures graceful degradation — if any source fails, empty array is substituted and partial results are returned.

Phase 3: Scoring and synthesis

4 sub-models score each dimension:

  • Pipeline Threat Score (30% weight): Phase 3 competitors (8 pts each), trial volume (2 pts each), FDA approvals (5 pts each), competitor recalls (-5 pts each)
  • First-Mover Advantage (inverted, 20% weight): Patent breadth (6 pts/patent), exclusivity duration (2.5 pts/year), trial phase lead (6.25 pts/phase), FDA approvals (10 pts/approval)
  • Adverse Event Divergence (25% weight): Deaths (7 pts each), serious ratio (ratio x 50), hospitalizations (4 pts/report), log-volume (log2 x 3)
  • Literature Momentum (25% weight): Volume (3 pts/pub), recency (5 pts/recent), acceleration ratio (25), journal diversity (3 pts/journal)

Composite score = round(pipelineThreat * 0.30 + adverseEventDivergence * 0.25 + literatureMomentum * 0.25 + (100 - firstMoverAdvantage) * 0.20)

Phase 4: Response formatting

All results returned as structured JSON with normalized field names, signal arrays, and source attribution.

Phase 5: Pricing

PPE charges applied via Apify Actor.charge() for cost tracking per tool.


17. Tips for Best Results

  1. Use specific drug names — More specific queries (e.g., "pembrolizumab") return better results than generic ("PD-1 inhibitor")

  2. Include indication for threat reports — Adding indication to generate_pipeline_threat_report improves ClinicalTrials.gov accuracy

  3. Filter by phase for competitive analysis — Use phase filter to focus on Phase 3 competitors for imminent market entry threats

  4. Use limit parameter for signal detection — Higher limits (500) give better divergence scores for detect_adverse_event_signals

  5. Check patent cliffs early — track_patent_exclusivity flags patent cliff warnings when <2 years remain — use for generic entry planning

  6. Monitor adverse event divergence levels — ELEVATED or higher triggers warrant medical affairs review

  7. Literature acceleration is a leading indicator — Publication momentum often precedes clinical milestones

  8. Combine with drug-intelligence-mcp — For FDA labeling and recall data on approved drugs, chain to drug-intelligence-mcp

  9. FAERS under-reporting is real — Adverse event reports indicate suspicion, not confirmed causation

  10. Patent expiry estimates exclude PTEs/SPCs/pediatric exclusivity — Actual exclusivity may be longer than USPTO filing dates suggest


18. Combine with Other Apify Actors

For comprehensive pharma and healthcare intelligence:

  • drug-intelligence-mcp — FDA drug labels, adverse events, NDC codes, drug interactions, recalls
  • healthcare-compliance-mcp — Medical device compliance, 510(k) clearances, MAUDE events
  • academic-research-mcp — PubMed papers, NIH grants, institutional research
  • patent-search-mcp — Patent landscape, FTO analysis, freedom to operate

Research chain:

pharma-pipeline-intelligence-mcp → drug-intelligence-mcp → healthcare-compliance-mcp

AI agents researching competitive threats can: (1) assess pipeline threat and safety signals, (2) verify FDA approval status and drug labeling, (3) check for overlapping device compliance issues.

Cross-sell workflow examples:

Investment Due Diligence:

  1. pharma-pipeline: generate_pipeline_threat_report(company="Novo Nordisk", drug="semaglutide", indication="obesity")
  2. drug-intelligence: search_drug_labels(drug_name="semaglutide")
  3. academic-research: search_papers(topic="GLP-1 clinical outcomes")

Patent Cliff Strategy:

  1. pharma-pipeline: track_patent_exclusivity(query="pembrolizumab")
  2. patent-search: patent_landscape(drug_name="pembrolizumab")
  3. pharma-pipeline: monitor_drug_recalls(query="pembrolizumab")

Safety Signal Investigation:

  1. pharma-pipeline: detect_adverse_event_signals(query="drug X", limit=500)
  2. academic-research: search_papers(topic="drug X adverse events")
  3. healthcare-compliance: get_device_recalls(manufacturer="company X")

Regulatory Planning:

  1. pharma-pipeline: compare_regulatory_pathways(query="PD-1 inhibitor")
  2. drug-intelligence: search_drug_recalls(drug_name="pembrolizumab")
  3. healthcare-compliance: search_clinical_trials(condition="oncology", sponsor="company X")

Elevator Pitch

For smithery.ai and mcp.so listings: Pharma Pipeline Intelligence MCP gives AI agents real-time competitive intelligence on any drug or therapeutic area — composite Pipeline Threat Scores (0-100) built from 6 government databases (ClinicalTrials.gov, FDA, FAERS, USPTO, PubMed) queried simultaneously in under two minutes. Covers clinical trial landscapes, FDA approval status, adverse event signals with MedDRA reaction tracking, patent cliffs with exclusivity timelines, and literature momentum with acceleration scoring. Built for biotech investors validating theses, BD teams monitoring competitive landscapes, medical affairs tracking safety signals, and patent attorneys assessing generic entry risk. PPE pricing at $0.04-$0.15 per call vs $15,000-$50,000/year commercial platforms — no API key required, works immediately, public GitHub repo with llms.txt for AI agent discovery.


Competitive Comparison

DimensionOur MCPApifyForge VersionCitelineCortellisGlobalData
Price$0.04-$0.15/call$0.045/call (flat)$15,000-$50,000/year$15,000+/year$20,000+/year
API typeMCP (AI-native)MCPREST (expensive)RESTREST
Access modelPay-per-callPay-per-callSubscription requiredSubscription requiredSubscription required
Tool count8 tools8 toolsFull database accessFull database accessFull database access
Data sources6 government APIs7 (incl. EMA - unavailable)Commercial + governmentCommercial + governmentCommercial
Scoring models4 sub-models (Pipeline Threat, FMA, AE Divergence, Literature Momentum)4 sub-modelsManual analysisManual analysisManual analysis
Composite reportYes (threat report fans out to all sources)YesRequires manual synthesisRequires manual synthesisRequires manual synthesis
AI agent integrationNative MCP protocolNative MCPNo MCP supportNo MCP supportNo MCP support
No API key requiredYes (all free government APIs)YesNo (commercial data)NoNo
Public GitHub repoYes (with llms.txt for AI discovery)No (private actor)N/AN/AN/A
LLM/AI agent SEOYes (public + discoverable)NoNoNoNo
Phase normalizationYes (Arabic + Roman numerals)YesN/AN/AN/A
Graceful degradationYes (Promise.allSettled)YesN/AN/AN/A
Setup time5 minutesUnknown (private)Days to weeksDays to weeksDays to weeks
Composite threat score0-100 with 4 sub-models0-100 with 4 sub-modelsNoneNoneNone
Adverse event divergenceNORMAL/ELEVATED/CONCERNING/CRITICALSameNoneNoneNone
Patent cliff warningYes (<2 years triggers)YesNoneNoneNone
Literature acceleration20% threshold detectionSameNoneNoneNone

Key differentiators vs ApifyForge:

  • Public GitHub + llms.txt = AI agents can discover us, ApifyForge cannot be found
  • Tiered pricing ($0.04-$0.15) vs flat $0.045 — composite reports cost more, simple lookups cost less
  • Value-based pricing aligned with tool complexity

Key differentiators vs commercial platforms:

  • 99.99% cheaper ($0.04-$0.15 vs $15,000-$50,000/year)
  • AI-native MCP integration vs REST API requiring custom integration
  • Built-in scoring models vs manual analysis
  • No approval process, no sales calls, no contracts
  • Works immediately — no API key required

SEO Keywords

pharma pipeline intelligence MCP, pharmaceutical competitive intelligence, clinical trials API, FDA drug approvals, adverse event signals, patent cliff monitoring, pipeline threat score, biotech investment AI, drug safety surveillance, no API key needed, AI agent MCP server, LLM drug pipeline, Claude pharma, Cursor biotech, pharmaceutical AI agent, ClinicalTrials.gov API, USPTO patent search, PubMed literature trends, FAERS adverse events, drug recall tracking, regulatory pathway analysis, pharma BD intelligence, medical affairs surveillance, generic entry strategy, First-Mover Advantage, Literature Momentum Score, Apify MCP, MCP server pharmaceutical, biotech due diligence AI, competitive landscape AI


License

Apache 2.0